# Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

> **NCT00951405** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 23 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A With Inhibitors
- Haemophilia B With Inhibitors

## Interventions

- **DRUG:** activated recombinant human factor VII, long acting
- **DRUG:** activated recombinant human factor VII, long acting
- **DRUG:** activated recombinant human factor VII, long acting

## Key facts

- **NCT ID:** NCT00951405
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-01
- **Primary completion:** 2011-03-29
- **Final completion:** 2011-03-29
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2018-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00951405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00951405, "Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00951405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*